Nicotine therapeutic benefits: Difference between revisions

 
(2 intermediate revisions by the same user not shown)
Line 1,200: Line 1,200:


===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]===  
===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]===  
*
*Depressed smokers relapsed significantly earlier than the nondepressed. Nicotine gum was significantly more effective than placebo gum among all smokers. The benefits of nicotine gum were particularly apparent among the depressed. Only 12.5% of depressed smokers quit successfully with placebo gum for 3 months, whereas 29.5% quit with nicotine gum. Depressed smokers reported more stress, less coping resources, more physical and psychological symptoms, and more frequent smoking in the presence of negative affect than did the nondepressed.
*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]
*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]
*Citation:
**Citation: Kinnunen, T., Doherty, K., Militello, F. S., & Garvey, A. J. (1996). Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement. Journal of Consulting and Clinical Psychology, 64(4), 791–798. https://doi.org/10.1037/0022-006X.64.4.791


===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]===  
===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]===  
Line 1,876: Line 1,876:


='''Suggested additions to this page'''=  
='''Suggested additions to this page'''=  
===2925: [https://link.springer.com/article/10.1186/s12890-025-04071-4 Modulatory roles of the vagus nerve and nicotine in bleomycin-induced pulmonary fibrosis in rats]===


===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===
===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===
Line 1,888: Line 1,890:
===2019: [https://medium.com/parkinsons-uk/protecting-brain-cells-the-story-of-nicotine-b3b51f5b8259 Protecting brain cells — the story of nicotine]===
===2019: [https://medium.com/parkinsons-uk/protecting-brain-cells-the-story-of-nicotine-b3b51f5b8259 Protecting brain cells — the story of nicotine]===
*[https://web.archive.org/web/20221021040501/https://www.parkinsons.org.uk/nicotine-good-bad-and-ugly Nicotine - Good, Bad, Ugly]
*[https://web.archive.org/web/20221021040501/https://www.parkinsons.org.uk/nicotine-good-bad-and-ugly Nicotine - Good, Bad, Ugly]
===2018: [https://pubmed.ncbi.nlm.nih.gov/29770521/ Nicotine-mediated neuroprotection of rat spinal networks against excitotoxicity]===


===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]===  
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]===